Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-11-21
2003-01-07
Rotman, Alan L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S310000
Reexamination Certificate
active
06503942
ABSTRACT:
FIELD OF THE INVENTION
This invention provides O-&agr;-acyloxyalkyl ethers of 4-[2-(Dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol, as well as pharmaceutical compositions and uses thereof.
BACKGROUND OF THE INVENTION
Various patents and literature references describe the biological activities of venlafaxine, and its salts and analogs. Venlafaxine hydrochloride tablets are marketed by Wyeth-Ayerst Laboratories as EFFEXOR.
The absolute configuration of the (+) enantiomer of venlafaxine was established as S by a single crystal X-ray analysis of the hydrobromide salt and the anomalous dispersion technique (Yardley et al., J. Med. Chem., 1990, 33, 2899).
(R/S)-1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol and its metabolites 1-[2-(dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanol and 1-[1-(4-methoxyphenyl)-2-(methylamino)ethyl]cyclohexanol are disclosed and claimed in U.S. Pat. No. 4,535,186 (Husbands et al.). U.S. Pat. No. 5,530,013 (Husbands et al.) claims the use of venlafaxine in the inducement of cognition enhancement. U.S. Pat. No. 5,506,270 (Upton et al.) claims venlafaxine's use in methods of treating hypothalamic amenorrhea in non-depressed women.
U.S. Pat. No. 5,788,986 (Dodman) and U.S. Pat. No. 5,554,383 (Dodman) teaches and claims the use of serotonin reuptake inhibitors in modifying the behavior of dogs.
DETAILED DESCRIPTION OF THE INVENTION
This invention provides pharmaceutically active O-&agr;-acyloxyalkyl ethers of the venlafaxine metabolite 4-[2-(Dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol (“O-Desmethyl venlafaxine” or “ODV”) having the structural formula I
wherein
the configuration at the steriogenic center (*) may be R, S, or RS (the racemate);
R
1
is selected from C
1
-C
6
alkyl, C
1
-C
6
alkoxy, C
3
-C
6
cycloalkyl, or the moiety:
R
2
is selected from H, or C
1
-C
6
alkyl; or,
R
1
and R
2
may be concatenated such that
form a moiety having formula (b):
R3 is selected from H or C
1
-C
6
alkyl; and
R4 and R5 are independently selected from H, C
1
-C
6
alkyl, C
3
-C
6
cycloalkyl, C
1
-C
6
alkoxy, C
1
-C
6
thioalkoxy, —CN, —OH, —CF
3
, —OCF
3
, halogen, —NH
2
, —NO
2
, or —N(CH
3
)
2
, or pharmaceutically acceptable salts or hydrates thereof.
In some preferred embodiments of the present invention R1 is t-butyl, methoxy, or isobenzofuranone.
In other preferred embodiments of the invention R2 is C1-C3 alkyl and in still more preferred embodiments of the invention R2 is methyl. Specific examples of compounds of Formula I include:
{4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenoxy}methyl pivalate;
1-{4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenoxy}ethyl propionate; and
3-{4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenoxy}-2-benzofuran-1(3H)-one.
Particularly, this invention provides compounds and/or compositions of both the O-&agr;-acyloxyalkyl R-ether of Formula I and the O-&agr;-acyloxyalkyl S-ether of Formula I, both being substantially free of the other. In addition, the invention provides the O-&agr;-acyloxyalkyl RS-ether of 4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]-phenol of Formula I.
Substantially free, as used herein means the compound or composition is made up of significantly greater proportion of the desired isomer than of the optical antipode. In a preferred embodiment of the invention, “substantially free” means that the compound or composition is made up of at least about 90% of the desired isomer and about 10% or less of the optical antipode. In still more preferred embodiments of the present invention, the compound or composition is made up of at least about 95% of the desired isomer and about 5% or less of the optical antipode. In yet further embodiments of the present invention the compound or composition is made up of at least about 99% of the desired isomer and about 1% or less of the optical antipode. Preferably the characterized or separated enantiomer will exhibit physical properties of a fully characterized compound, i.e. a uniform melting point and a uniform rotation of plane-polarized light in a polarimeter. Most preferably, the enantiomers will be recrystallized to analytical purity.
C
1
-C
6
alkyl as used herein, such as in the definition of R
1
, includes straight, branched chain alkyl groups within the specified range of carbon atoms.
Halogen, as used herein refers to chlorine, bromine, iodine and fluorine.
Pharmaceutically acceptable salts refer to salts prepared from pharmaceutically acceptable acids, including inorganic acids and organic acids, such as, but not limited to, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, mitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic and the like.
Compounds of the invention are readily prepared by methods known in the art, for instance, as described by Bodor, et al.,
J. Org. Chem
.(48) 5280-5284 (1983).
The appropriate R-, S-, or (R/S)-4-[2-(Dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol is reacted with the appropriate O-&agr;-acyloxyalkyl halide (examples: pivaloyloxymethyl chloride, 3-bromophthalide, iodomethyl pivalate) (Scheme Ia) or (acyloxy)benzyl &agr;-halide (Scheme Ib) in an inert solvent (acetonitrile, tetrahydrofuran, dimethylformamide) in the presence of an alkali metal carbonate (sodium or potassium carbonate) or transition metal carbonate (silver carbonate) in accordance with Schemes Ia and Ib.
wherein R
1
is selected from C
1
-C
6
alkyl, C
1
-C
6
alkoxy, C
3
-C
6
cycloalkyl, or the moiety:
R
2
is selected from H, or C
1
-C
6
alkyl;
or R
2
and R
3
are concatenated to form a moiety having formula (b);
R3 is selected from H or C
1
-C
6
alkyl; and
R4 and R5 are independently selected from H, C
1
-C
6
alkyl, C
3
-C
6
cycloalkyl, C
1
-C
6
alkoxy, C
1
-C
6
thioalkoxy, —CN, —OH, —CF
3
, —OCF
3
, halogen, —NH
2
, —NO
2
, or mono or dialkylamino wherein each alkyl group has 1 to 6 carbon atoms.
In some preferred embodiments of the invention increased yield may be obtained by reacting the appropriate R-, S-, or (RIS)-4-[2-(Dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol with the appropriate O-&agr;-acyloxyalkyliodide in an inert solvent (acetonitrile, tetrahydrofuran, dimethylformamide) in the presence of alkali metal carbonate such as potassium carbonate, or transition metal carbonate such as silver carbonate. Most preferred is the use of O-&agr;-acyloxyalkyliodide in the presence of silver carbonate at low temperatures in the range of approximately 0-5° C.
In a minor modification, compounds of formula I wherein R1 and R2 are concatenated to form
and one or both of R
4
and R
5
are NH
2
, can be obtained by catalytic reductions, such as with palladium catalysts, from corresponding analogs wherein R
4
or R
5
are NO
2
.
Racemic 1-[2-(dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanol can be produced as described in Example 26 of U.S. Pat. No. 4,535,186 (Husbands et al.), which is incorporated herein by reference. It will be understood that the enantiomers may be separated from each other by standard resolution techniques known in the art.
Alternatively, these R and S enantiomers may be obtained by O-demethylation of the separated enantiomers of venlafaxine using either boron tribromide or ethane thiol anion.
O-&agr;-acyloxyalkyl ethers of Formula I and their pharmaceutically useful salts and hydrates are useful for the biological and pharmacological activities for which venlafaxine and its salts are known in the art. These O-&agr;-acyloxyalkyl ethers may be used in treating or inhibiting central nervous system disorders, including depression, (including but not limited to major depressive disorder, biopolar disorder, and dysthymia), fibromyalgia, anxiety, panic disorder, agoraphobia, post-traumatic stress disorder, premenstrual dysphoric diso
Abou-Gharbia Magid A.
Ullrich John W.
Yardley John P.
Barrett Rebecca R.
Robinson Binta
Rotman Alan L.
Wyeth
LandOfFree
Ethers of O-Desmethyl venlafaxine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ethers of O-Desmethyl venlafaxine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ethers of O-Desmethyl venlafaxine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3062814